Precigen, Inc. Terminates Material Definitive Agreement
Ticker: PGEN · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1356090
| Field | Detail |
|---|---|
| Company | Precigen, Inc. (PGEN) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, material-event
TL;DR
Precigen terminated a big deal, could be good or bad.
AI Summary
Precigen, Inc. announced on October 4, 2024, the termination of a material definitive agreement. The company, formerly known as Intrexon Corp, is based in Germantown, Maryland.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding the company's business relationships and financial projections.
Key Players & Entities
- Precigen, Inc. (company) — Registrant
- Intrexon Corp (company) — Former name of Registrant
- October 4, 2024 (date) — Date of earliest event reported
- 20374 Seneca Meadows Parkway, Germantown, Maryland 20876 (location) — Principal executive offices
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the exact nature or counterparty of the material definitive agreement that was terminated.
When did the termination of the agreement become effective?
The filing states the date of the earliest event reported is October 4, 2024, which is when the termination is noted.
What are the potential financial implications of this termination for Precigen, Inc.?
The filing does not provide specific details on the financial implications of the termination.
Was there a specific reason cited for the termination of the agreement?
The filing does not disclose the reasons behind the termination of the material definitive agreement.
Does this termination affect any ongoing business operations or partnerships of Precigen, Inc.?
While the filing confirms the termination of a material definitive agreement, it does not detail the specific impact on ongoing operations or partnerships.
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-10-10 16:33:18
Filing Documents
- dp219254_8k.htm (8-K) — 22KB
- 0000950103-24-014811.txt ( ) — 188KB
- pgen-20241004.xsd (EX-101.SCH) — 3KB
- pgen-20241004_lab.xml (EX-101.LAB) — 33KB
- pgen-20241004_pre.xml (EX-101.PRE) — 22KB
- dp219254_8k_htm.xml (XML) — 3KB
02
Item 1.02 Termination of a Material Definitive Agreement As previously disclosed, on April 3, 2023, Precigen, Inc. ("Precigen" or the "Company"), entered into an Amended and Restated License Agreement (the "A&R License Agreement") with Alaunos Therapeutics, Inc. ("Alaunos"), which amended and restated in its entirety the License Agreement, dated October 5, 2018, by and among the same parties, for the grant of certain licenses by Precigen to Alaunos. On October 4, 2024, the A&R License Agreement was terminated. Following the termination of the A&R License Agreement, Precigen has regained all rights previously licensed to Alaunos and Alaunos retains no rights to utilize any of Precigen's technology. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Precigen, Inc. By: /s/ Donald P. Lehr Donald P. Lehr Chief Legal Officer Dated: October 10, 2024